Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GS-9688 in virally suppressed adults with chronic hepatitis B
ACTRN12618000143224Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Apr 2018
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of selgantolimod in Chronic Hepatitis B (CHB) (3 arms), sponsored by Gilead Sciences. Primary endpoint: Safety and tolerability of multiple oral doses of GS-9688 at Week 24. Started Apr 2018; status: completed.
02
Drugs
selgantolimod
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on ACTRN12618000143224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12618000143224.